Nanoscope Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 47

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $1.5M

  • Investors
  • 4

Nanoscope Therapeutics General Information

Description

Developer of a therapeutic gene and delivery platform designed to be used for vision restoration. The company is developing optogenetic gene therapies using multi-characteristic opsin to re-sensitize the retina in order to detect low light levels, enabling patients to recover from diseases like dry and age-related macular degeneration.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Trinity Towers
  • 2777 North Stemmons Freeway
  • Dallas, TX 75207
  • United States
+1 (817)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Trinity Towers
  • 2777 North Stemmons Freeway
  • Dallas, TX 75207
  • United States
+1 (817)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nanoscope Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Grant 14-Sep-2021 $1.5M Completed Clinical Trials - Phase 3
2. Early Stage VC (Series A) 21-Jul-2020 Completed Clinical Trials - Phase 3
1. Grant 28-May-2020 $2M Completed Clinical Trials - Phase 3
To view Nanoscope Therapeutics’s complete valuation and funding history, request access »

Nanoscope Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view Nanoscope Therapeutics’s complete cap table history, request access »

Nanoscope Therapeutics Patents

Nanoscope Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4704877-A2 Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof Pending 24-Apr-2023
US-20260295090-A1 Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof Pending 24-Apr-2023
WO-2024226667-A2 Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof Inactive 24-Apr-2023
WO-2024226667-A3 Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof Inactive 24-Apr-2023
US-12459977-B2 Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof Active 06-Nov-2016 C07K14/47
To view Nanoscope Therapeutics’s complete patent history, request access »

Nanoscope Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nanoscope Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
AG Collective Capital Venture Capital Minority
CKG Management Venture Capital Minority
National Eye Institute Government
U.S. Department of Health and Human Services Government
To view Nanoscope Therapeutics’s complete investors history, request access »

Nanoscope Therapeutics FAQs

  • When was Nanoscope Therapeutics founded?

    Nanoscope Therapeutics was founded in 2017.

  • Where is Nanoscope Therapeutics headquartered?

    Nanoscope Therapeutics is headquartered in Dallas, TX.

  • What is the size of Nanoscope Therapeutics?

    Nanoscope Therapeutics has 47 total employees.

  • What industry is Nanoscope Therapeutics in?

    Nanoscope Therapeutics’s primary industry is Drug Discovery.

  • Is Nanoscope Therapeutics a private or public company?

    Nanoscope Therapeutics is a Private company.

  • What is Nanoscope Therapeutics’s current revenue?

    The current revenue for Nanoscope Therapeutics is .

  • How much funding has Nanoscope Therapeutics raised over time?

    Nanoscope Therapeutics has raised $12.8M.

  • Who are Nanoscope Therapeutics’s investors?

    AG Collective Capital, CKG Management, National Eye Institute, and U.S. Department of Health and Human Services have invested in Nanoscope Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process